Placental abruption screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==screeninig== | ==screeninig== | ||
*First trimester (pregnancy-associated placental protein-A [PAPP-A]) | *First trimester (pregnancy-associated placental protein-A [PAPP-A]) | ||
*second trimester (total hCG and alpha fetoprotein [AFP]) serum biochemistry were determined. | *second trimester (total hCG and alpha fetoprotein [AFP]) serum biochemistry were determined.The two screening periods were compared for the prediction of a range of severe adverse perinatal outcomes (intrauterine growth restriction [IUGR], abruption, severe pre-eclampsia/HELLP syndrome, delivery < 32 weeks, or stillbirth). | ||
*MRI is a complementary technique that should be considered when ultrasound is inconclusive or incomplete. | |||
== References == | == References == | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 15:21, 3 August 2020
|
Placental abruption Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Placental abruption screening On the Web |
|
American Roentgen Ray Society Images of Placental abruption screening |
|
Risk calculators and risk factors for Placental abruption screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief:Rana aljebzi, M.D.[2]
screeninig
- First trimester (pregnancy-associated placental protein-A [PAPP-A])
- second trimester (total hCG and alpha fetoprotein [AFP]) serum biochemistry were determined.The two screening periods were compared for the prediction of a range of severe adverse perinatal outcomes (intrauterine growth restriction [IUGR], abruption, severe pre-eclampsia/HELLP syndrome, delivery < 32 weeks, or stillbirth).
- MRI is a complementary technique that should be considered when ultrasound is inconclusive or incomplete.